Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:KRON

Kronos Bio (KRON) Stock Price, News & Analysis

Kronos Bio logo

About Kronos Bio Stock (NASDAQ:KRON)

Advanced Chart

Key Stats

Today's Range
$0.87
$0.88
50-Day Range
$0.67
$0.89
52-Week Range
$0.65
$1.46
Volume
54,089 shs
Average Volume
370,931 shs
Market Capitalization
$53.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.63
Consensus Rating
Hold

Company Overview

Receive KRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kronos Bio and its competitors with MarketBeat's FREE daily newsletter.

KRON Stock News Headlines

The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”
Kronos Bio sends Cambridge lab space back to market
Concentra To Acquire Kronos Bio
See More Headlines

KRON Stock Analysis - Frequently Asked Questions

Kronos Bio, Inc. (NASDAQ:KRON) issued its quarterly earnings results on Tuesday, March, 18th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.13. The business had revenue of $2.27 million for the quarter, compared to the consensus estimate of $1 million. Kronos Bio had a negative trailing twelve-month return on equity of 64.22% and a negative net margin of 701.53%.

Kronos Bio (KRON) raised $175 million in an initial public offering on Friday, October 9th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kronos Bio investors own include Bank of America (BAC), AT&T (T), Taseko Mines (TGB), Energy Transfer (ET), ARMOUR Residential REIT (ARR), Prospect Capital (PSEC) and New Gold (NGD).

Company Calendar

Last Earnings
3/18/2025
Today
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KRON
CIK
1741830
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

High Price Target
$2.25
Low Price Target
$1.00
Potential Upside/Downside
+84.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$86.08 million
Net Margins
-701.53%
Pretax Margin
-701.53%
Return on Equity
-64.22%
Return on Assets
-47.17%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.93
Quick Ratio
12.93

Sales & Book Value

Annual Sales
$9.85 million
Price / Sales
5.45
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.45 per share
Price / Book
0.61

Miscellaneous

Outstanding Shares
61,050,000
Free Float
46,155,000
Market Cap
$53.72 million
Optionable
Optionable
Beta
1.64

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:KRON) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners